Equipment review: the molecular adsorbents recirculating system (MARS).

摘要: The molecular adsorbents recirculating system (MARS®) is a form of artificial liver support that has the potential to remove substantial quantities albumin-bound toxins have been postulated contribute pathogenesis cell damage, haemodynamic instability and multi-organ failure in patients with acute (ALF) acute-on-chronic (AoCLF). These include fatty acids, bile tryptophan, bilirubin, aromatic amino acids nitric oxide. Data from controlled clinical trials are limited so far. One two studies performed on small numbers AoCLF suggest survival benefit, but no data available ALF setting. Our preliminary experience MARS therapy, instituted late course five severely impaired function, including three precipitated by sepsis dysfunction due absence pre-existing chronic disease, indicates some efficacy. However, overall rate (1 5; 20%) remained poor. More obtained larger cohorts enrolled randomised will be required both settings identify categories who might benefit most treatment, ascertain appropriate timing intervention determine impact outcome, cost-effectiveness.